tbuckley/cabot-search huggingface dataset:
Abstract 20258: Stenosis Severity and Kidney Function in Atherosclerotic Renal Artery Stenosis
Authors: Mark Shipeng Yu, Alan H Matsumoto, Karol Pencina, Katherine Tuttle, Wencan He, Kaleigh Evans, Kaili Ren, David A Folt, Pamela S Brewster, Timothy P Murphy, Donald E Cutlip, Lance D Dworkin, Michael R Jaff, Michael Steffes, Joseph I Shapiro, William Henrich, Christopher J Cooper
Journal: Circulation (2014)

Introduction: Ischemic nephropathy due to atherosclerotic renal artery stenosis (ARAS) is associated with poor event free survival. However, previous studies suggest that stenosis severity has a poor relation to kidney function. We sought to test the interactions of stenosis severity, and revascularization, on kidney function in people with ARAS. Hypothesis: Stenosis severity is associated with poor renal function in people with ARAS. Methods: The Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) clinical trial is a prospective trial of individuals with atherosclerotic renal-artery stenosis. Patients were followed to a maximum of 8 years. Angiographic images were measured at a single core lab (University of Virginia) using quantitative computer-assisted angiography. Estimated glomerular filtration rate (eGFR) was measured using creatinine and cystatin-C, performed at a single core lab (University of Minnesota), and calculated using the CKD-EPI Creatinine-Cystatin C formula. The analyses are controlled by age and gender. Results: At baseline CKD-EPI eGFR was strongly and negatively correlated with percent stenosis (-0.2472, p&lt;0.0001) and positively correlated with minimal luminal diameter (0.2974, p&lt;0.0001). Interestingly, peak systolic pressure gradient and mean pressure gradients were not (p=ns for both). At three years follow-up baseline percent stenosis remained significant by univariate analysis (0.1380, p=0.01), however, it was not significant by multivariate analysis. Conclusions: Stenosis severity is strongly related to kidney function at the time of presentation in patients with atherosclerotic renal artery stenosis. However, by three years follow-up, this relationship appears to be lost.
Abstract 1682: Metformin synergistically enhances antitumor efficacy of sorafenib in vitro
Authors: YUNMI KO, Bo Ra Choi, Jun Ah Lee
Journal: Cancer Research (2014)

Abstract Background: Previously, we observed anti-tumor effect of sorafenib in osteosarcoma cells. However, a number of studies suggested that cancer cells might escape from the therapeutic effects of sorafenib though activation of mTOR pathways. Metformin displays significant growth inhibitory effects in several cancer cells by modulating AMPK/Akt/mTOR signaling pathway. We evaluated the effect of metformin in osteosarcoma cells as a single agent, as well as in combination with sorafenib. Methods: The effects of metformin on proliferation, migration and apoptosis of osteosarcoma cells were evaluated using MTT, wound-healing and FACS analysis. To elucidate the mechanisms of cell growth inhibition induced by metformin, we investigated expression of several key signaling proteins in OS cells. The synergistic interactions of metformin and sorafenib were determined by calcusyn analysis. Results: We found that metformin significantly decreased the cell survival, wound-healing capacity of OS cells. Metformin also markedly activated AMPK and decreased the expression of Akt, ERK1/2, mTOR and its downstream target markers. And we observed that addition of sorafenib enhanced antiproliferative and proapoptotic effects of metformin by synergistic modulation of AMPK/Akt/mTOR signaling pathway. Conclusion: We found that metformin exerts therapeutic potentials in OS cells. Currently, studies are underway to evaluate the possibilities of using metformin as an adjuvant therapeutic agent for osteosarcoma, in combination with chemotherapeutic agents or radiotherapy. Citation Format: YUNMI KO, Bo Ra Choi, Jun Ah Lee. Metformin synergistically enhances antitumor efficacy of sorafenib in vitro. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1682. doi:10.1158/1538-7445.AM2014-1682
Endocarditis and pericarditis complicating pneumococcal bacteraemia, with special reference to the adhesive abilities of pneumococci: results from a prospective study
Authors: B. Kan, J. Ries, B. Henriques Normark, F-Y. Chang, C. Feldman, W.C. Ko, J. Rello, D.R. Snydman, V.L. Yu, A. Ortqvist
Journal: Clinical Microbiology and Infection (2006)
Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
Authors: Amit Dipak Amin, Soumya S. Rajan, Winnie S. Liang, Praechompoo Pongtornpipat, Matthew J. Groysman, Edgar O. Tapia, Tara L. Peters, Lori Cuyugan, Jonathan Adkins, Lisa M. Rimsza, Yves A. Lussier, Soham D. Puvvada, Jonathan H. Schatz
Journal: Cancer Research (2015)

Abstract The anaplastic lymphoma kinase (ALK) is chromosomally rearranged in a subset of certain cancers, including 2% to 7% of non–small cell lung cancers (NSCLC) and ∼70% of anaplastic large cell lymphomas (ALCL). The ALK kinase inhibitors crizotinib and ceritinib are approved for relapsed ALK+ NSCLC, but acquired resistance to these drugs limits median progression-free survival on average to ∼10 months. Kinase domain mutations are detectable in 25% to 37% of resistant NSCLC samples, with activation of bypass signaling pathways detected frequently with or without concurrent ALK mutations. Here we report that, in contrast to NSCLC cells, drug-resistant ALCL cells show no evidence of bypassing ALK by activating alternate signaling pathways. Instead, drug resistance selected in this setting reflects upregulation of ALK itself. Notably, in the absence of crizotinib or ceritinib, we found that increased ALK signaling rapidly arrested or killed cells, allowing a prolonged control of drug-resistant tumors in vivo with the administration of discontinuous rather than continuous regimens of drug dosing. Furthermore, even when drug resistance mutations were detected in the kinase domain, overexpression of the mutant ALK was toxic to tumor cells. We confirmed these findings derived from human ALCL cells in murine pro-B cells that were transformed to cytokine independence by ectopic expression of an activated NPM–ALK fusion oncoprotein. In summary, our results show how ALK activation functions as a double-edged sword for tumor cell viability, with potential therapeutic implications. Cancer Res; 75(14); 2916–27. ©2015 AACR.
Abstract 13925: Impact of In-hospital Acute Phase Cardiac Rehabilitation on Long-term Cardiovascular Outcomes in Acute Myocardial Infarction Patients
Authors: Chika Kawashima, Yasushi Mtsuzawa, Hiroyuki Suzuki, Eiichi Akiyama, Nobuhiko Maejima, Noriaki Iwahashi, Kengo Tsukahara, Kiyoshi Hibi, Masami Kosuge, Toshiaki Ebina, Satoshi Umemura, Kazuo Kimura
Journal: Circulation (2014)

Background: Cardiac rehabilitation (CR) post ST elevation acute myocardial infarction (STEMI) remains an underused tool. In part, this arises from uncertainty regarding the efficacy of CR, particularly acute phase CR. We therefore investigated the impact of in-hospital CR post STEMI on long-term cardiovascular outcomes. Methods: We enrolled 472 patients with successful reperfusion therapy within 12 hours of onset of STEMI, between October 2001 and October 2008. All patients were included to participate in the acute phase CR program during hospitalization and were followed for cardiovascular events which consist of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Total number of walking CR times during hospitalization was counted and included into analyses. Results: During the 2592 person-years of follow-up, 83 patients (17.6%) experienced cardiovascular events. In-hospital CR was performed fewer in patients with cardiovascular events compared with those without events [median n...
Deoxyribonuclease II is a lysosomal barrier to transfection
Authors: Dasein Pinto-González Howell, Ronald J Krieser, Alan Eastman, Michael A Barry
Journal: Molecular Therapy (2003)

DNA delivered in nonviral vectors or as naked DNA must overcome a number of extracellular and intracellular barriers to transfection. Since many vectors deliver DNA into cells by the endocytic route, DNA degradation by lysosomal nucleases has been proposed as a significant barrier to transfection, despite the fact that this has not yet been formally demonstrated to occur. To test this hypothesis, we have investigated the role of deoxyribonuclease II (DNase II), the primary acidic endonuclease active in the lysosome, in transfection. Two genetic systems were engineered in which mammalian cells either overexpressed DNase II or were knocked out for the enzyme. In both models, higher levels of DNase II correlated with decreased transfection efficiency by nonviral DNA delivery vectors. These data provide direct evidence implicating lysosomal DNase II as a barrier to transfection.
Sustained effects of grass pollen AIT
Authors: S. R. Durham
Journal: Allergy (2011)

To cite this article: Durham SR, on behalf of the GT‐08 investigators. Sustained effects of grass pollen AIT. Allergy 2011; 66 (Suppl. 95): 50–52. Abstract We report the sustained efficacy of the SQ‐standardized grass allergy immunotherapy tablet Grazax ® ( Phleum pratense 75 000 SQ‐T/2,800 BAU, ALK, Denmark) from a 5‐year randomized, double‐blind, placebo‐controlled phase III trial. Adults with moderate‐to‐severe grass pollen allergy inadequately controlled by symptomatic medications were followed for 2 years after the completion of 3 years of treatment. The active group demonstrated a 31% reduction in median rhinoconjunctivitis symptom score over the season compared with placebo. Individual symptom scores favoured active treatment. Combined symptom and medication scores demonstrated a 33% reduction in medians with active treatment. Persistent clinical efficacy was accompanied by prolonged increases in allergen‐specific IgG 4 antibodies and IgE‐blocking factor, confirming clinical and immunological tolerance for at least 2 years after the treatment completion. No safety issues were identified during follow‐up.
Familial cluster of cutaneous Mycobacterium avium infection resulting from use of a circulating, constantly heated bath water system
Authors: Y. Sugita, N. Ishii, M. Katsuno, R. Yamada, H. Nakajima
Journal: British Journal of Dermatology (2000)

Journal Article Familial cluster of cutaneous Mycobacterium avium infection resulting from use of a circulating, constantly heated bath water system Get access Y. Sugita, Y. Sugita Department of Dermatology, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa‐ku, Yokohama 236‐0004, Japan Yasuyuki Sugita. E‐mail: ysugita@med.yokohama‐cu.ac.jp Search for other works by this author on: Oxford Academic Google Scholar N. Ishii, N. Ishii Department of Dermatology, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa‐ku, Yokohama 236‐0004, Japan Search for other works by this author on: Oxford Academic Google Scholar M. Katsuno, M. Katsuno Department of Dermatology, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa‐ku, Yokohama 236‐0004, Japan Search for other works by this author on: Oxford Academic Google Scholar R. Yamada, R. Yamada Department of Dermatology, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa‐ku, Yokohama 236‐0004, Japan Search for other works by this author on: Oxford Academic Google Scholar H. Nakajima H. Nakajima Department of Dermatology, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa‐ku, Yokohama 236‐0004, Japan Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 142, Issue 4, 1 April 2000, Pages 789–793, https://doi.org/10.1046/j.1365-2133.2000.03428.x Published: 01 April 2000
Abstract 427: Upregulation of KLF4 and inhibition of HDAC activity by methylseleninic acid in human esophageal squamous cells
Authors: Chenfei Hu, Wei Zhang, Qing Xu, Lechuang Chen, Kai Ma, Mei Liu, Hongxia Zhu, Ningzhi Xu
Journal: Cancer Research (2014)

Abstract In the present study, we investigated the potential mechanisms of the inhibition of cell growths induced by methylseleninic acid, MSA. Our result showed that MSA could induce cell growth inhibition and apoptosis in esophageal squamous cell carcinoma (ESCC) cells and inhibit tumor growth measured by xenograft volume in nude mice. Upon treated with MSA, HDACs activity was decreased and GCN5, one of histone acetyltransferases, upregulated as well in human esophageal squamous cell lines. Meanwhile a significant increase of H3K9 acetylation (H3K9ac) was detected. Notably,upregulation of KLF4, which has been wildly reported usually downregulated expression in cell lines and tumor tissues of ESCC, was also observed after MSA treatment. Additionally the acetylated histone H3 could locate more at KLF4 promoter region than non-acetylated one did, showed by chromatin immunoprecipitation assay. Moreover knockdown of GCN5 reduced the protein levels of both H3K9ac and KLF4, along with less cell growth inhibition. Taken all, our result indicates that MSA can exert its anti-tumor effects, at least in part, by up-regulation KLF4, probably via inhibiting the HDAC activity and up-regulation GCN5. By our best of knowledge, this is the first report of selenium-induced selective, post-translational acetylation of histone H3 at Lys9, which may depend on the activities of and the balance between HDACs and HATs. Note: This abstract was not presented at the meeting. Citation Format: Chenfei Hu, Wei Zhang, Qing Xu, Lechuang Chen, Kai Ma, Mei Liu, Hongxia Zhu, Ningzhi Xu. Upregulation of KLF4 and inhibition of HDAC activity by methylseleninic acid in human esophageal squamous cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 427. doi:10.1158/1538-7445.AM2014-427
Systemic deficiency of the map kinase activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice
Authors: Kumaravelu Jagavelu, Uwe F. Tietge, Matthias Gaestel, Helmut Drexler, Bernhard Schieffer, Udo Bavendiek
Journal: Circulation (2007)

Atherosclerosis is a chronic inflammatory disease and represents the major cause of cardiovascular morbidity and mortality. A critical regulator of inflammatory processes represents the mitogen-activated protein kinase–activated protein kinase-2 (MK2). Therefore, we investigated the functional role of MK2 in atherogenesis in hypercholesterolemic mice as well as potentially underlying mechanisms in vivo and in vitro. Activation of MK2 (phospho-MK2) was predominantly detected in the endothelium and macrophage-rich plaque areas within aortas of hypercholesterolemic LDL receptor–deficient mice ( ldlr  −/− ). Systemic MK2 deficiency of hypercholesterolemic  ldlr  −/−  mice ( ldlr  −/−  /mk2  −/− ) significantly decreased the accumulation of lipids and macrophages in the aorta after feeding an atherogenic diet for 8 and 16 weeks despite a significant increase in proatherogenic plasma lipoproteins compared with  ldlr  −/−  mice. Deficiency of MK2 significantly decreased oxLDL-induced foam cell formation in vitro, diet-induced foam cell formation in vivo, and expression of scavenger receptor A in primary macrophages. In addition, systemic MK2 deficiency of hypercholesterolemic  ldlr  −/−  mice significantly decreased the aortic expression of the adhesion molecule VCAM-1 and the chemokine MCP-1, key mediators of macrophage recruitment into the vessel wall. Furthermore, silencing of MK2 in endothelial cells by siRNA reduced the IL-1β–induced expression of VCAM-1 and MCP-1. MK2 critically promotes atherogenesis by fostering foam cell formation and recruitment of monocytes/macrophages into the vessel wall. Therefore, MK2 might represent an attractive novel target for the treatment of atherosclerotic cardiovascular disease.
Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia [published erratum appears in Blood 1987 Mar;69(3):996]
Authors: CH Pui, SC Raimondi, FG Behm, J Ochs, WL Furman, NJ Bunin, RC Ribeiro, PA Tinsley, J Mirro
Journal: Blood (1986)
Budapest nurse held over deaths of elderly patients
Authors: Carl Kovac
Journal: BMJ (2001)

Police in Hungary have arrested a 24 year old nurse in connection with the deaths of as many as 40 elderly patients in the internal medicine department at Budapest's Nyiro Gyula Hospital over the past year. She is being held under maximum security at the central police headquarters in Budapest pending the outcome of further investigation and tests by a court psychiatrist.

Hungary's health minister has ordered a review of medication practices and night-time nursing at all the country's hospitals in the wake of the arrest.

The nurse, identified only as Timea F was formally arrested on 17 February. Police officers acting on information from hospital staff had summoned her to police headquarters …
Abstract 13022: Phase Contrast Velocity Mapping is Accurate Just Proximal and Distal to Stent Artifact During Cardiac Magnetic Resonance Imaging
Authors: Kevin K Whitehead, Ravi S Doddasomayajula, Matthew J Gillespie, Yoav Dori, Andrew C Glatz, Jonathan J Rome, Mark A Fogel, Matthew A Harris
Journal: Circulation (2013)

Background:  Cardiac magnetic resonance (CMR) is frequently used to evaluate and follow post-operative congenital heart disease. Phase contrast velocity mapping (PC-MRI) is increasingly relied upon for evaluation of physiology, often requiring measurements in the vicinity of various metal stents. Little data are available on the accuracy of PC-MRI flow measurements in the vicinity of stents. We therefore sought to determine this accuracy using in vitro experiments.   Methods:  An in vitro flow phantom was used with three stent types: 1) 316L stainless steel, 2) nitinol self-expanding and 3) platinum-iridium. Steady and pulsatile flow was delivered with a CMR-compatible pump (CardioFlow 5000, Shelley Medical). Mean flows ranged from 0.5 to 7 L/min. Flows were measured using a transit time flow meter (ME19PSN, Transonic, Inc.). For each condition, 5 PC-MRI acquisitions were made: within the stent, immediately adjacent to both edges of stent artifact, and 1 cm upstream and downstream of the artifact. Mean PC-MRI flows were calculated by segmenting the tube lumen using clinical software (ARGUS, Siemens, Inc.). Locations and stent type were compared using linear regression, Bland-Altman and intraclass correlation.   Results:  PC-MRI flows within the stent artifact were inaccurate for all stents studied, generally underestimating flow meter measured flow. Agreement between PC-MRI and flow meter measured flows was excellent for all stent types, both immediately adjacent to and 1cm away from the edge of the stent artifact. (See Table) Agreement was highest for the platinum-iridium stent and lowest for the nitinol stent.   Conclusions:  PC-MRI flows are highly accurate just upstream and downstream of a variety of stents used clinically, including stainless steel. Nitinol had the greatest influence on PC-MRI flows. These findings support the use of PC-MRI to directly measure flows in stented vessels, which supports our previously reported clinical experience.
Abstract #5508: Enhancement of cisplatin effect by the inhibitor of system L amino acid transporter 1
Authors: Kohichi Yamauchi, Hiroyuki Sakurai, Toru Kimura, Pattama Wiriyasermkul, Shushi Nagamori, Yasunao Kogashiwa, Yoshikatsu Kanai, Naoyuki Kohno
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract The amino acids such as leucine that stimulate mTOR signaling pathway are transported into cells through plasma membrane system L amino acid transporters. LAT1, a subtype of system L transporters, has been investigated in several cancers because of its onco-fetal nature. Based on the studies of its functional inhabitation, LAT1 has been proposed to be a new molecular target of cancer therapy. We show here that squamous cell carcinoma cell lines from head and neck cancers, Hep-2, Ca9-22 and SCC-68, express both LAT1 and its associated protein 4F2hc by western blot analysis. An inhibitor of system L, 2-aminobicyclo-(2, 2, 1)-heptane-2-carboxylic acid (BCH), inhibited leucine uptake by Hep-2 cells. BCH decreased viability of Hep-2 cells in a concentration-dependent manner, although more than 5 days are necessary to obtain statistically significant effects. We found BCH greatly enhanced cisplatin effects even when BCH alone did not exert significant effect on the viability of the cells. Although the reduction in Hep-2 cell viability was additive when BCH treatment preceded cisplatin administration, synergistic effect in decreasing the number of viable cells was obtained when BCH was given after cisplatin treatment. It was previously reported that the inhibition of mTOR by rapamycin or related compounds enhanced the effect of cisplatin. BCH treatment, in fact, decreased the phosphorylation of mTOR, p70S6K and 4EBP1, suggesting that BCH enhanced anti-tumor action of cisplatin by suppressing mTOR pathway. This potentiation may be used to reduce cisplatin exposure to alleviate many unwanted toxicity of the drug because BCH can enhance cisplatin effect selectivity in cancer cells by inhibiting the cancer specific amino acid transporter. BCH-cisplatin combination is a potentially useful treatment for cancer.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5508.
Neutralizing the SARS Virus
Authors: Tracy Hampton
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patch testing in the rabbit using a modified human patch test method.
Authors: A.J. INGRAM, P. GRASSO
Journal: British Journal of Dermatology (1975)

A 5 h, semi-occlusive human patch test repeated daily for 5 days, was modified for use in the rabbit Using this method, the relative irritancy of three cosmetic samples of known human irritancy was determined in the rabbit. In addition, attention was paid to assessment methods and a detailed histological scoring system is described as well as two methods of visual assessment. In order to compare the effectiveness of these methods, the reaction to a series of concentrations of sodium lauryl sulphate was examined. All three assessment methods gave similar results and the merits of combining histological and visual assessment are discussed.
Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo
Authors: Sunjay Kaushal, Gilad E. Amiel, Kristine J. Guleserian, Oz M. Shapira, Tjorvi Perry, Fraser W. Sutherland, Elena Rabkin, Adrian M. Moran, Frederick J. Schoen, Anthony Atala, Shay Soker, Joyce Bischoff, John E. Mayer
Journal: Nature Medicine (2001)